Transcript • Feb. 26, 2026 10:00 PM • Emergent Biosolutions, Inc. (EBS)
Transcript
Feb. 26, 2026 10:00 PM
Emergent Biosolutions, Inc. (EBS)
Joe Papa: packaging, and among college students, the population identified as one of the highest risk groups for opioid misuse. This preference rises to 81%. Additionally, we received FDA approval for two multi-use configurations of NARCA nasal spray offering both a 6-count and a 24-count multi-pack option designed to meet the needs of partners distributing higher volumes of naloxone. As opioid overdose death rates are declining nationally, we believe in the critical role OTC and Narcan plays in saving lives. Many from the field want to know what is the real-world impact of Naloxone in opioid overdose reversal and saving lives. New York State offers compelling evidence of its effectiveness. A peer-reviewed analysis from 2023 to March of 2025 found that Naloxone administration saved more than 6,500 lives and over 200,000 years of life in the New York State alone. It's worth noting that recent legislation signed by the New York governor now requires certain private employers to stock in opioid antagonists. Our efforts are aligned as we work hard to ensure businesses are equipped and prepared to respond to an opioid overdose emergency. We are also very proud of our ongoing work to support Canada in their efforts to help save lives. There have been recent shifts across British Columbia and other provinces to prioritize nasal naloxone access, and we look forward to continued engagement across Canada. We cannot afford to lose thousands of innocent lives to opioid crisis, and we believe our work in collaboration with all stakeholders is essential to reducing the number of lives lost to zero. Now I'd like to turn the call over to Rich to walk through the quarter for financial results.
Rich: Thanks, Joe. Good afternoon, everyone, and thank you for joining us today. We're excited to share the strong progress we made in 2025 and the continued momentum we're carrying into 2026. 2025 was a year of meaningful advancement for emergent, one where our transition from stabilization to turnaround gained real traction. Our resilient and strategically positioned portfolio, designed to protect against global public health threats, delivered sustainable revenue, expanded profitability, and powerful cash generation. These foundational strengths are positioning us for long-term value creation and giving us financial flexibility to pursue attractive growth opportunities. Throughout the year, we achieved substantial financial improvements. Adjusted EBITDA rose to $205 million, a $22 million or 12% year-over-year increase. Gross margin expanded by an impressive 900 basis points, and we reduced operating expenses by $140 million versus 2024. These results are further highlighted by the improvement of adjusted net income per share from a loss of 23 cents in 2024 to earnings of $1.53 in 2025. These outcomes reflect the strong potential and enhanced competitiveness of our business. We also significantly strengthened cash generation, reducing both net debt and net leverage while returning capital to shareholders. Our lean, disciplined operating model continues to support solid profitability and robust cash flow, creating meaningful optionality as we invest in the business and drive shareholder value. Turning to slide 11, our fourth quarter performance was generally as expected, although the impacts on public interest customers that Joe described led to lower than anticipated commercial segment revenues. Total revenues were $149 million, with MCM tracking squarely to guidance. Narcan performance was temporarily impacted by software demand amid the prolonged government shutdown and near-term market uncertainty. Factors we view as transient and not reflective of the long-term growth potential in this category. Adjusted EBITDA of $11 million, or an 8% margin, landed at the high end of our guidance. Adjusted gross margin improved 300 basis points to 43%, driven by product mix and continued operational efficiency. Operating expenses decreased 10% year over year, underscoring our ongoing commitment to disciplined cost management. Slide 12 reflects a year of strong execution. Total revenues were $743 million, remembering that 2024 included $115 million of settlement and divested revenue. And despite the revenue decline versus 2024, adjusted EBITDA landed at the high end of guidance, Again, up 22 million or 12% year-over-year and expanding by 1,000 basis points. Gross margin improved 900 basis points and operating expenses decreased 140 million or 37%. Even in a lower revenue environment, we delivered meaningful improvements in profitability, reinforcing the solid foundation and operating discipline we've established during the first phase of our multi-year transformation. Slide 13 highlights the durability of our revenue bid. Total revenue of $743 million reflects steady performance across MCM, complemented by increasing international momentum, where global MCM sales represented 34% of total revenue and continue to be a growth catalyst. As expected, U.S. government orders moderated and established a new baseline of demand going forward. Naloxone's full-year performance reflected pricing dynamics and the California market impact, along with temporary disruptions that amplified seasonality impacts during the year. Importantly, we continue to invest in Narcan's brand strength, product extensions, commercial capabilities, and customer support, reinforcing the long-term health of this franchise. Other revenues $60 million aligned to expectations, reflecting the absence of prior one-time items and divested facility revenue. Slide 14 showcases a significant improvement across our financial metrics. We ended 2025 with total liquidity of $305 million, including $205 million in cash and $100 million of undrawn revolver capacity. And this is after making a substantial $100 million voluntary prepayment on our term loan. Operating cash flow grew 190% to $171 million. Net leverage improved to 1.9 times from 3.3 times in the prior year. And adjusted net income per share rose to $1.53, reversing a loss in 2024. These results reflect not only strong operating execution, but also increasing financial flexibility that enhances our ability to drive shareholder value. On slide 15, we highlight the significant steps taken to optimize our capital structure. During 2025, we paid down $110 million of gross debt, a combination of the $100 million voluntary prepayment against our term loan and the repurchase of $10 million principal amount of our unsecured bonds. These efforts reduced our total debt to 590 million and net debt to $384 million, a 32% and 49% reduction from year end 2023, respectively. As a result of these efforts, 2025 ending net leverage of 1.9 times improved substantially from 5.7 times in the first quarter of 2024. This progress illustrates how our enhanced cash generating profile supports both accelerated deleveraging and continued investment in growth initiatives, all while maintaining healthy liquidity. Slide 16 outlines our consistent capital allocation priorities, growth, debt reduction, and shareholder returns. In 2025, we strengthened our portfolio through the additions of Cloxada and Rocketbacks and continued investing in our internal R&D pipeline and international MCM capabilities. Debt repayment remained a key focus. In addition to our $100 million turn-loan prepayment, we used $8.7 million of cash to repurchase and retire $10.3 million principal amount of our unsecured bonds. And we advanced shareholder returns by repurchasing 3.1 million shares under our stock buyback program. As announced today, our Board has approved a new $50 million authorization through March 31, 2027. We will remain opportunistic with additional share repurchases based on market conditions. Please turn to slide 17. Throughout 2025, we consistently raised guidance and full year results for adjusted net income, adjusted gross margin, and adjusted EBITDA exceeded the midpoint of our October outlook, while net income was below the range due to the loss on debt extinguishment. Overall, these outcomes demonstrate our strong execution and proactive cost management even in a lower revenue environment. Slide 19 presents our initial 2026 outlook, with total revenues expected in the range of $720 to $760 million. MCM revenue is expected to be flat to slightly down, continued strength in international demand. Of note, 2025 benefited from an exceptionally strong $60 million international customer order, which we do not currently forecast to repeat in 2026. Commercial revenues are expected to be flat to slightly up, with volume offsetting the anticipated price adjustments. And we expect Narcan to maintain its leading market share. Adjusted gross margin is expected to land between 45 and 47%, reflecting product mix and expected pricing dynamics. Adjusted EBITDA is anticipated to be between 135 to $155 million. To put this guidance in context, note that the one-time international order I just referenced contributed $50 million of adjusted EBITDA in 2025. Net income is expected to be between a loss of $30 million and a loss of $10 million, with adjusted net income between $25 million and $45 million. We anticipate a healthy start to the year with first quarter revenue of $135 to $155 million. Of note, we also expect that revenues in the first half of the year will represent about 40% of the full year total. In closing, please turn to slide 20. 2025 year was a year of consistent execution, expanding profitability, and material progress towards our transformation goals. Our lean and focused operating model delivered higher gross margins, stronger profitability, and robust cash flow, fueling debt reduction and shareholder returns. With net leverage below two times, strong liquidity, and meaningful operating momentum entering 2026, we are well positioned to build on this progress and drive compelling long-term value for our shareholders. With that, I'll now turn the call back to Joe.
Joe Papa: Thank you, Rich. Turning to slide 22, as part of our mission to protect and save lives, we develop and deliver highly complex products that address some of the world's most pressing public health threats like smallpox, anthrax, botulism, and Ebola. As the market leader in nasal naloxone, we are deeply steeped in the evolving nature of the opioid crisis. We believe every medicine cabinet first aid kit in person should have Narcan on hand. On to our medical countermeasure biodefense look for today and the future, the risk of bioterror and public health threats is rising. Our proprietary survey insights show how policy leaders view bioterror as easier to carry out than nuclear attacks. Fortunately, we have a strong bipartisan support for U.S. leadership in biodefense. On to slide 23, You'll see a summary of the government funding and several international commitments which demonstrate stability and provides merchants with an opportunity to engage meaningfully with our customers and partners. Of note, U.S. government spend is rising in 2026 across all major federal programs, including BARDA, Project BioShield, Strategic National Stockpile, and State Opioid Response Grants. reinforcing a strong and sustained commitment to U.S. preparedness. International investment is also rising, with the EU's HERA program and NATO allies boosting their readiness budgets. It's also worth noting that more than $50 billion in U.S. class action opioid settlement dollars, which is an additional funding stream, will be available to address the opioid crisis over the next eight to 10 years. Moving to slide 24, in 2026, we outline our outlook on future growth and cash deployment. Our plan makes on track to selectively invest the cash we are generating from our profit business segments into two key initiatives, organic international internal growth and inorganic initiatives through business development and external partnerships. We'll continue to invest in international MCM expansion efforts geographically and pursue Naloxone innovation opportunities. Slide 25 takes a closer look at our lifecycle initiatives with 10VACSA, IBANGA, and RACI-VACMAP, as well as the pipeline focus areas. In summary, on slide 26, we achieved many key milestones in the fourth quarter and throughout 2025, including operating performance, tax generation, and debt reduction. We are confident in our ability to execute on our core business and long-term growth initiatives while ensuring continue improvement and operational profitability. As we advance our transformation, we remain committed to the highest standards of quality, ethics, and compliance, and we look forward to the years ahead. Operator, please open up the line for questions.
Operator: Thank you. At this time, we will conduct the question and answer session. As a reminder, to ask a question, you will need to press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. I am showing no questions at this time. I would now like to turn the call back to Joe Papa, CEO, for closing remarks.
Joe Papa: Thank you, everyone, for joining us today. I think that the presentation was clear, straightforward, and answered questions that people had in this space. We very much appreciate everyone's attendance today. Thank you very much. I look forward to speaking with many of you in the near future. Thank you. Have a great day, everyone.
Operator: Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.
